JP4869638B2 - Cell activator, whitening agent, antioxidant, amylase inhibitor, and humectant - Google Patents

Description

The present invention relates to a cell activator, a whitening agent, an antioxidant, an amylase inhibitor, and a humectant. More specifically, the present invention relates to a cell activator, a whitening agent, an antioxidant, an amylase inhibitor, and a moisturizing agent, characterized by containing Elaeagnus latifolia as an active ingredient.

  Naturally-derived components are known to have various pharmacological and cosmetic effects, and so far many plants and fungi have been widely applied to fields such as external preparations for skin and foods and drinks. In particular, in order to prevent and ameliorate skin symptoms such as wrinkles, stains, stains, and skin elasticity reduction, various active ingredients such as cell activators, whitening agents, and antioxidants have been searched and formulated. Also, in the field of food and drink, various active ingredients have been studied as amylase inhibitors in order to prevent and improve diabetes, obesity, arteriosclerosis, etc. by suppressing an increase in blood sugar. As the cell activator known so far, the essence of Ponkan (see Patent Document 1), as the whitening agent, water and / or organic solvent extract of white crane reishi (see Patent Document 2), antioxidant As an amylase inhibitor, there is known a hydrophilic solvent extract of laurel leaves (see Patent Document 4) as an amylase inhibitor.

JP 2001-131045 A JP 2003-89630 A JP-A-11-180886 JP-A-4-27389

  As described above, naturally-derived components are known to have various pharmacological and cosmetic effects, but there are many naturally-derived components whose effects are not yet known, and excellent cell activation. Development of an active ingredient having an action, a whitening action, an amylase inhibitory action and the like has been expected. The present invention was made in order to find such an active ingredient, and is a cell activator, whitening agent, antioxidant, amylase inhibitor, which can be widely applied in the fields of external preparations for skin and foods and beverages, and the like. The object is to provide a moisturizing agent.

In order to find a cell activator, a whitening agent, an antioxidant, an amylase inhibitor, and a moisturizer that can be widely applied in the field of external preparations for skin and foods and drinks, the present inventors have found various substances derived from nature. Was examined. As a result, an excellent cell activating action, whitening action, antioxidant action, amylase inhibitory action, and moisturizing action were found in the extract of Elaeagnus latifolia , and further studies were made to complete the present invention. It was. That is, the present invention provides a cell activator, a whitening agent, an antioxidant, an amylase inhibitor, and a moisturizing agent containing an extract of Elaeagnus latifolia as an active ingredient.

  According to the present invention, it is possible to provide a cell activator, a whitening agent, an antioxidant, an amylase inhibitor, and a moisturizer having an excellent effect, and these are blended in a composition such as a skin external preparation or food. Thus, it is possible to provide a composition exhibiting excellent effects in prevention and improvement of various skin symptoms such as wrinkles, tarmi, skin firmness, stains and kusumi and diabetes, obesity, arteriosclerosis and the like.

As a plant used as a raw material of the present invention, Elaeagnus latifolia which is a plant belonging to the genus Gummyaceae is used. When used, it can be dried and pulverized as it is, but usually an extract is preferably used. For extraction, any part of plant trunk, branch, leaf, flower, fruit, bark, sap, root, stem, bud, etc. may be used, but use of leaf and fruit is simple and effective. From the viewpoint of sex, it is better to use fruit. In the extraction, it may be used as it is, but considering the extraction efficiency, it is preferable to perform the extraction after performing processing such as shredding, drying, and pulverization. The extraction can be performed by immersing in an extraction solvent or by an extraction method using a supercritical fluid or a subcritical fluid. In order to increase the extraction efficiency, the mixture may be homogenized in stirring or an extraction solvent. The extraction temperature is suitably about 5 ° C. to the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but it is appropriate to set it to about 1 hour to 14 days.

  Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin, ethers such as ethyl ether and propyl ether. And solvents such as esters such as butyl acetate and ethyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these can be selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used. Furthermore, you may use 1 type, or 2 or more types of supercritical fluids and subcritical fluids, such as water, a carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia.

  The extract of Ela airginas latifolia by the above solvent can be used as it is, but the concentrated and dried product can be used again by dissolving it in water or a polar solvent, and these physiological functions are not impaired. It may be used after performing purification treatment such as decolorization, deodorization, desalting, and fractionation treatment by column chromatography. In addition, the treated product and fractionated product can be freeze-dried after each treatment and fractionation and dissolved in a solvent before use.

  The extract of Eraeaginas latifolia thus obtained has an excellent cell activation effect, whitening effect, antioxidant effect, amylase inhibitory effect, and moisturizing effect, cell activator, whitening agent, antioxidant, It can be used as an amylase inhibitor and a humectant. In addition, cell activators, whitening agents, antioxidants, amylase inhibitors, and moisturizers containing an extract of Era aegina latifolia as an active ingredient can be applied to the skin and hair and can be taken orally. For this reason, cell activators, whitening agents, antioxidants, amylase inhibitors, and moisturizers containing an extract of Ela airginas latifolia as an active ingredient are used as external preparations for skin, foods, beverages, pharmaceuticals, quasi drugs, It can be applied to products in various fields such as cosmetics.

  A cell activator comprising an extract of Era aegina latifolia as an active ingredient exerts an excellent activation action on various cells, but particularly exerts an excellent effect on dermal fibroblasts and epidermal cells.

  A whitening agent comprising an extract of Ela airginas latifolia as an active ingredient is effective in improving pigmentation symptoms such as stains and freckles, and in particular, is excellent in suppressing melanin production.

  Antioxidants containing an extract of Era aegina latifolia as an active ingredient exhibit an excellent antioxidant effect, but particularly exhibit an excellent effect on the DPPH radical scavenging action and the superoxide anion scavenging action.

  An amylase inhibitor comprising an extract of Era aegina latifolia as an active ingredient exerts an excellent amylase inhibitory action, and particularly exhibits an excellent effect on the inhibitory action of α-amylase.

  In addition, skin that exhibits an excellent effect in the prevention and improvement of skin symptoms such as wrinkles, tarmi, skin firmness, spots, kumi, dryness, fine lines, etc. An external preparation can be obtained, and can also be used as a skin external preparation for improving aging prevention, a cell-utilizing skin external preparation, an antioxidant skin external preparation, or a whitening skin external preparation. In addition, the extract of Elaea guineas latifolia can also be used in medicines, foods and beverages for the purpose of preventing and improving diabetes, obesity, arteriosclerosis, etc. and maintaining general health and nutrition. it can.

  The amount of Ela Airginas latifolia extract blended into a composition such as a topical skin preparation or food can be adjusted depending on the type and purpose of use. On the other hand, it is preferably 0.0001 to 50.0% by weight, and more preferably 0.001 to 25.0% by weight.

  The dosage form of the composition containing the extract of Ela Eginas latifolia is arbitrary, and in the case of external preparations for skin, cleaning agents, bath preparations, solubilizing systems such as lotions, emulsifying systems such as emulsions, and calamine lotions It can be provided as various dosage forms such as aerosols, ointments, powders and granules filled with a dispersion system such as a propellant. If the composition is an oral medicine or food, use a general dosage form such as liquids such as drinks and drops, solid preparations such as gums and candy, capsules, powders, granules, and tablets. Can do.

  It should be noted that the composition containing the extract of Elaea guineas latifolia contains, in addition to the extract of ellaeginas latifolia, as necessary, usually pharmaceuticals, quasi-drugs, skin cosmetics, bath preparations, cleaning agents. , Oily ingredients blended in foods, moisturizers, powders, pigments, emulsifiers, solubilizers, detergents, UV absorbers, thickeners, drugs, fragrances, resins, alcohols, nutrient enhancement substances, seasonings Etc. can be appropriately blended. Moreover, in the range which does not impair the effect of this invention, combined use with another cell activator, a whitening agent, antioxidant, and an amylase inhibitor is also possible.

  Hereinafter, production examples of the extract of Elaea Eginas latifolia, tests for evaluating each action, formulation examples as a skin external preparation and food, and use tests will be described in more detail, but the technical scope of the present invention is This is not a limitation.

[Production Example 1]
40 kg of a 50 wt% aqueous ethanol solution was added to 1 kg of dried pulverized product of Era aegina latifolia and stirred at room temperature for 2 hours. The extract was collected by filtration and extracted again in the same manner, and then the solvent was removed to obtain an extract of Era aegina latifolia.

[Production Example 2]
20 liters of water was added to 1 kg of dried pulverized product of Era aegina latifolia, and the mixture was extracted by refluxing at 90 ° C. for 1 hour. The extract was collected by filtration, and after removing the solvent, an Elaaeguinas latifolia extract was obtained.

[Production Example 3]
Nine liters of methanol was added to 1 kg of dried pulverized leaves of Ela airginas latifolia and immersed for 7 days at room temperature. The extract was collected by filtration, and after removing the solvent, an Elaaeguinas latifolia extract was obtained.

[Production Example 4]
The supercritical extractor was charged with elaea guineas latifolia and extracted with a supercritical fluid of carbon dioxide at 40 ° C. under a pressure of 15 MPa. The extract was recovered to obtain an Elaaeguinas latifolia extract.

  First, the dermal fibroblast activation effect of the Elaea guineas latifolia extract is shown. The sample was evaluated as sample 1 obtained by extracting ellagioginas latifolia according to Production Example 1 and as sample 2 obtained by extraction according to Production Example 2.

The evaluation was performed according to the following procedure. Normal human dermal fibroblasts were seeded in a 96-well microplate at 2.0 × 10 ⁴ cells per well. The seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 1% fetal bovine serum. After culturing for 24 hours, the culture medium was replaced with a test medium to which a sample having an arbitrary concentration was added, and further cultured for 48 hours. Next, the medium containing 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT) was replaced with a medium containing 400 μg / mL and cultured for 2 hours. Extraction was performed with 2-propanol, and absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values. The evaluation results are shown in Table 1 as relative values with the cell activation effect in the blank with no sample as 100. In the table, * and ** indicate a significance probability of less than 5% (P <0.05) with respect to the significance probability P value in the t test, and a significance probability of less than 1% (P <0.01). It is represented by ** (the same applies to the following tables).

  As is clear from Table 1, a significant dermal fibroblast activation effect was observed in the medium supplemented with Elaaeguinas latifolia extract. In particular, when 0.06 mg / mL of samples 1 and 2 were added, a significant dermal fibroblast activation effect was observed with a risk rate of less than 1% compared to the blank. From this, it was clarified that the extract of Eraaeguinas latifolia has an excellent dermal fibroblast activation effect.

  Next, the activation action of the epidermis cells of the extract of Era aegina latifolia will be described.

The evaluation was performed according to the following procedure. Normal human epidermal cells were seeded in a 96-well microplate at 2.0 × 10 ⁴ cells per well. As a seeding medium, commercially available Humdia-KG2 manufactured by Kurabo Industries, Ltd. was used. After culturing for 24 hours, the culture medium was replaced with the test medium to which the sample was added, and further cultured for 24 hours. Next, the medium containing 100 μg / mL of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT) was exchanged and cultured for 2 hours. Formazan generated by the opening of the tetrazolium ring was removed. Extraction was performed with 2-propanol, and absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values. The evaluation results are shown in Table 2 as relative values when the cell activation effect when no cell activator is added is defined as 100.

  As is clear from Table 2, a significant epidermal cell activation effect was observed in the medium to which the extract of Era aegina latifolia was added. In particular, when the sample was added at 0.25 mg / mL, a significant epidermal cell activation effect was observed at a risk rate of less than 1% compared to the blank. From this, it was clarified that the extract of Era aegina latifolia has an excellent epidermal cell activation effect.

  Next, the evaluation of the melanin production inhibitory action of the extract of Era aegina latifolia is shown.

  The evaluation was performed according to the following procedure. B16 mouse melanoma F0 strain (B16F0) cells were seeded in a 35 mm dish at 2000 cells per dish. After culturing for 24 hours, the culture medium was replaced with Dulbecco's modified Eagle medium (DMEM) supplemented with 5 wt% fetal calf serum (FCS) to which a sample of an arbitrary concentration was added. After culturing for 7 days, the cells were collected using 0.25% trypsin, transferred to a 1.5 mL microtube, and centrifuged to obtain a cell precipitate. Furthermore, instead of the medium to which the sample was added, Dulbecco's modified Eagle medium (DMEM) to which 5 wt% fetal calf serum (FCS) was added was used as a blank, and visual determination was similarly performed. Further, as shown in Table 3, the visual judgment was performed by a five-step evaluation. Table 4 shows the determination results.

  As is clear from Table 4, no blackening was observed when Sample 1 was added at 0.1 mg / mL and Sample 2 was added at 1.0 mg / mL. From this, it was clarified that the extract of Era aegina latifolia has an excellent melanin production inhibitory action.

  Next, the antioxidant effect of the extract of Era aegina latifolia will be described.

The evaluation was performed according to the following procedure. 100 μL of a sample solution diluted to an arbitrary concentration with a 50 wt% aqueous ethanol solution was added to a 96-well microplate. Next, 100 μL of a 1,1-diphenyl-2-picrylhydrazyl (DPPH) solution prepared in ethanol to a concentration of 0.2 mM was added to a 96-well microplate. The mixture was left in the dark with stirring, and the absorbance at 516 nm was measured after 24 hours. When the absorbance of the blank with no sample added was (A) and the absorbance when the sample was added was (B), the value of formula (1) was defined as the radical elimination rate. The evaluation results are shown in Table 4.
Formula (1) {1- (B) / (A)} × 100 (%)

  As can be seen from Table 5, when the Elaaeguinas latifolia extract was added, a high radical scavenging rate was exhibited. From this, it was found that the extract of Era aegina latifolia has an excellent antioxidant action based on excellent radical scavenging.

  Next, the amylase inhibitory action of the extract of Era aegina latifolia will be described.

The evaluation was performed according to the following procedure. 1 mL of a sample solution dissolved in the same buffer was added to 1 mL of a 2% starch solution (0.1 M Tris-HCl buffer pH 7.0), and incubated at 37 ° C. for 5 minutes. 0.1 mL (10 Units) of α-amylase (derived from porcine pancreas, manufactured by SIGMA) was added and incubated at 37 ° C. for 60 minutes. Thereafter, 1 mL of a coloring solution (0.01N iodine solution) was added, diluted 20 times with distilled water, and the absorbance at 660 nm was measured. When the absorbance when only the buffer solution was added was (A) and the absorbance when the sample solution was added was (B), the amylase inhibition rate was calculated using the following formula. The respective evaluation results are shown in Table 6.
Amylase inhibition rate (%) = [1- (B) / (A)] × 100

  As is clear from Table 6, it was revealed that the extract of Era aegina latifolia has an excellent amylase inhibitory action based on the α-amylase inhibitory action.

  Subsequently, prescription examples of an external preparation for skin and a food containing the extract of Ela airginas latifolia according to the present invention will be shown.

[Formulation Example 1] Emulsion (1) Squalane 10.0 (wt%)
(2) Methylphenylpolysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20E.O.) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) Carboxyvinyl polymer 0.15
(10) Purified water 100 (11) Arginine (1 wt% aqueous solution) 20.0
(12) Ela Eginas latifolia extract [Production Example 1] 5.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After emulsification, start cooling and add (11) and (12) sequentially and mix uniformly.

[Prescription Example 2] Lotion (1) Ethanol 15.0 (% by weight)
(2) Polyoxyethylene (40E.O.) hydrogenated castor oil 0.3
(3) Fragrance 0.1
(4) Purified water 100 residue (5) Citric acid 0.02
(6) Sodium citrate 0.1
(7) Glycerin 1.0
(8) Hydroxyethyl cellulose 0.1
(9) Ela Airginas latifolia extract [Production Example 3] 5.0
Production method: (2) and (3) are dissolved in (1). After dissolution, (4) to (8) are sequentially added, and then sufficiently stirred, (9) is added and mixed uniformly.

[Prescription Example 3] Cream (1) Squalane 10.0 (% by weight)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20% by weight aqueous solution) 15.0
(10) Purified water 100 (11) Carboxyvinyl polymer (1 wt% aqueous solution) 15.0
(12) Ela Eginas latifolia extract [Production Example 1] 1.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification is completed, add (11), start cooling, add (12) at 40 ° C., and mix uniformly.

[Formulation Example 4] Cosmetic liquid (1) Residual water (100%) (% by weight)
(2) Glycerin 10.0
(3) Sucrose fatty acid ester 1.3
(4) Carboxyvinyl polymer (1% by weight aqueous solution) 17.5
(5) Sodium alginate (1 wt% aqueous solution) 15.0
(6) Polyglyceryl monolaurate 1.0
(7) Macadamia nut oil fatty acid phytosteryl 3.0
(8) N-lauroyl-L-glutamic acid di (phytosteryl-2-octyldodecyl) 2.0
(9) Hardened palm oil 2.0
(10) Squalane (from olive) 1.0
(11) Behenyl alcohol 0.75
(12) Beeswax 1.0
(13) Jojoba oil 1.0
(14) 1,3-butylene glycol 10.0
(15) L-arginine (10% by weight aqueous solution) 2.0
(16) Ela Eginas latifolia extract [Production Example 1] 5.0
Production method: The aqueous phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Cooling is started after completion of emulsification, and (15) is added at 50 ° C. Cool further to 40 ° C, add (16) and mix evenly.

[Formulation Example 5] Aqueous gel (1) Carboxyvinyl polymer 0.5 (% by weight)
(2) Residual water 100 (3) Sodium hydroxide (10% by weight aqueous solution) 0.5
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Fragrance 0.1
(7) Ela Eginas latifolia extract [Production Example 4] 2.0
(8) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.1
Manufacturing method: (1) is added to (2), and after stirring uniformly, (3) is added. After stirring uniformly, (5) previously dissolved in (4) is added. After stirring uniformly, the previously mixed (6) to (8) are added and stirred and mixed uniformly.

[Formulation Example 6] Cleansing Fee (1) Squalane 81.0 (wt%)
(2) Polyoxyethylene glyceryl isostearate 15.0
(3) Purified water 3.0
(4) Ela Airginas latifolia extract [Production Example 4] 1.0
Manufacturing method: (1) and (2) are uniformly dissolved. (3) and (4) are sequentially added to this and mixed uniformly.

[Prescription Example 7] Face-wash foam (1) Stearic acid 16.0 (% by weight)
(2) Myristic acid 16.0
(3) Lipophilic glyceryl monostearate 2.0
(4) Glycerin 20.0
(5) Sodium hydroxide 7.5
(6) Palm oil fatty acid amidopropyl betaine 1.0
(7) Residue to be 100 (8) Elaea guineas latifolia extract [Production Example 3] 1.0
Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (5) to (7) are heated and dissolved at 80 ° C., and mixed and stirred uniformly with the oil phase components. Cooling is started, and (8) is added at 40 ° C. and mixed uniformly.

[Prescription Example 8] Make-up base cream (1) Squalane 10.0 (% by weight)
(2) Cetanol 2.0
(3) Glycerin tri-2-ethylhexanoate 2.5
(4) Lipophilic glyceryl monostearate 1.0
(5) Propylene glycol 11.0
(6) Sucrose fatty acid ester 1.3
(7) Residual remaining 100 (8) Titanium oxide 1.0
(9) Bengala 0.1
(10) Yellow iron oxide 0.4
(11) Fragrance 0.1
(12) Ela Airginas latifolia extract [Production Example 2] 1.2
Production method: The oil phase components (1) to (4) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C., and the pigments (8) to (10) are added thereto and dispersed uniformly with a homomixer. The oil phase component is added to the water phase component and emulsified with a homomixer. Cooling is started after the emulsification is completed, and the components (11) and (12) are added at 40 ° C. and mixed uniformly.

[Formulation Example 9] Emulsion foundation (1) Methylpolysiloxane 2.0 (wt%)
(2) Squalane 5.0
(3) Octyldodecyl myristate 5.0
(4) Cetanol 1.0
(5) Polyoxyethylene (20E.O.)
Sorbitan monostearate 1.3
(6) Sorbitan monostearate 0.7
(7) 1,3-butylene glycol 8.0
(8) Xanthan gum 0.1
(9) Methyl paraoxybenzoate 0.1
(10) Purified water 100 (11) Titanium oxide 9.0
(12) Talc 7.4
(13) Bengala 0.5
(14) Yellow iron oxide 1.1
(15) Black iron oxide 0.1
(16) Fragrance 0.1
(17) Ela Airginas latifolia extract [Production Example 4] 1.0
Production method: The oil phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are mixed and dissolved by heating at 75 ° C., and the pigments (11) to (15) are added thereto and uniformly dispersed with a homomixer. Add oil phase ingredients and emulsify. Cooling is started after the emulsification is completed, and components (16) and (17) are sequentially added at 40 ° C. and mixed uniformly.

[Formulation Example 10] Water-in-oil emollient cream (1) Liquid paraffin 30.0 (% by weight)
(2) Microcrystalline wax 2.0
(3) Vaseline 5.0
(4) Diglycerin oleate 5.0
(5) Sodium chloride 1.3
(6) Potassium chloride 0.1
(7) Propylene glycol 3.0
(8) 1,3-butylene glycol 5.0
(9) Methyl paraoxybenzoate 0.1
(10) Ela Eginas latifolia extract [Production Example 1] 1.0
(11) Residue remaining as 100 (12) Fragrance 0.1
Production method: Dissolve (5) and (6) in a part of (11) to 50 ° C., and gradually add to (4) heated to 50 ° C. with stirring. After mixing this, it disperse | distributes uniformly to (1)-(3) heated and melt | dissolved at 70 degreeC. (7) to (10) are added to the remainder of (11) heated and dissolved at 70 ° C. while stirring and emulsified with a homomixer. Cooling is started after completion of emulsification, and (12) is added at 40 ° C. and mixed uniformly.

[Formulation Example 11] Pack (1) Residue (weight%) as 100 purified water
(2) Polyvinyl alcohol 12.0
(3) Ethanol 17.0
(4) Glycerin 5.0
(5) Polyethylene glycol (average molecular weight 1000) 2.0
(6) Ela Eginas latifolia extract [Production Example 2] 5.0
(7) Fragrance 0.1
Production method: (2) and (3) are mixed, heated to 80 ° C, and then dissolved in (1) heated to 80 ° C. After uniformly dissolving, add (4) and (5), and start cooling while stirring. Cool to 40 ° C, add (6) and (7) and mix uniformly.

[Prescription Example 12] Bath agent (1) Fragrance 0.3 (% by weight)
(2) Ela Eginas latifolia extract [Production Example 1] 1.0
(3) Sodium bicarbonate 50.0
(4) Residual manufacturing method which makes sodium sulfate 100: (1)-(4) is mixed uniformly.

[Prescription Example 13] Hair wax (1) Stearic acid 3.0 (% by weight)
(2) Microcrystalline wax 2.0
(3) Cetyl alcohol 3.0
(4) Highly polymerized methylpolysiloxane 2.0
(5) Methylpolysiloxane 5.0
(6) Poly (oxyethylene / oxypropylene)
Methylpolysiloxane copolymer 1.0
(7) Methyl paraoxybenzoate 0.1
(8) 1,3-butylene glycol 7.5
(9) Arginine 0.7
(10) Purified water 100 residue (11) Elaea guineas latifolia extract [Production Example 1] 2.0
(12) Fragrance 0.1
Production method: The oil phase components (1) to (6) are mixed and heated and dissolved at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 75 ° C., the oil phase component is added, and the mixture is emulsified with a homomixer. Cooling is started after the emulsification is completed, and the components (11) and (12) are added at 40 ° C. and mixed uniformly.

[Prescription Example 14] Hair artic (1) Ethanol 50.0 (% by weight)
(2) Residue to be 100 (3) Elaea guineas latifolia extract [Production Example 3] 1.0
(4) Fragrance 0.1
Production method: Components (1) to (4) are mixed and homogenized.

[Prescription Example 15] Beverage (1) Ela Eginas latifolia extract [Production Example 1] 8.0 (wt%)
(2) Erythritol 1.0
(3) Citric acid 0.1
(4) Stevia 0.01
(5) The remaining manufacturing method which makes purified water 100: (1)-(5) is mixed uniformly.

  Next, a use test was conducted using a prescription blended with an extract of ella airginas latifolia, and the improvement effect was evaluated for rough skin caused by drying. At that time, Ela Airginas latifolia extract described in Table 7 was blended with the emulsion formulation shown in Formulation Example 1, and the use test was conducted as Examples 1-5. In addition, Ella Airginas latifolia extract was replaced with purified water, and a use test was conducted simultaneously as Comparative Example 1.

  For each sample, 20 female panelists with dry skin in their 30s to 50s whose skin symptom was remarkably recognized were grouped and used blindly for 1 week, and the skin condition before and after use was observed and evaluated. . As an index of skin symptom, rough skin due to dryness was evaluated in three stages of “improvement”, “slight improvement”, and “no change”, and Table 8 shows the number of panelists that obtained each evaluation.

  From Table 8, in the comparative example use group that does not contain elaea guineas latifolia extract, improvement was not recognized in 60% or more of the panelers, but in the example use group that blended elaea guinea latifolia extract, More than 60% of panelists showed a clear improvement in rough skin. From this, it was clarified that the Ela Airginas latifolia extract has an excellent moisturizing effect.

  Based on the above, the extract of Era aeginas latifolia has excellent cell activation, whitening, antioxidant, amylase inhibitory, and moisturizing effects, cell activator, whitening agent, antioxidant, amylase inhibitor It has been shown to be useful as a humectant as well as an agent. In addition, by combining Ela Eginas latifolia extract with a composition such as a topical skin preparation or food, various skin symptoms such as wrinkles, tarmi, skin firmness, stains, and kusumi, as well as diabetes, obesity, arteriosclerosis, etc. It has been found that it is possible to provide a composition that exhibits an excellent effect in preventing and improving the above.

Claims (5)

A cell activator for an external preparation for skin , characterized by containing Elaeagnus latifolia as an active ingredient. A whitening agent for an external preparation for skin , characterized by containing Elaeagnus latifolia as an active ingredient. An antioxidant for external preparation for skin , characterized by comprising Elaeagnus latifolia as an active ingredient. An amylase inhibitor for an external preparation for skin , characterized by comprising Elaeagnus latifolia as an active ingredient. A moisturizing agent for external preparations for skin , characterized by containing Elaeagnus latifolia as an active ingredient.